Trial Profile
A Dose Blinded Extension Study to the CBAF312A2201 Study to Evaluate Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Siponimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms BOLD EXTENSION
- Sponsors Novartis
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 28 Feb 2017 Status changed from recruiting to completed.
- 19 Dec 2016 This trial has been completed in Hungary (end date: 10 Oct 2016) according to European Clinical Trials Database.